Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetes
Pharma
Novo struggles to appease restless investors with new strategy
CEO Mike Doustdar acknowledged that the company’s leadership “have to convince” investors that “there is a bright future for Novo.”
James Waldron
,
Fraiser Kansteiner
Sep 21, 2026 10:50am
Novo CEO talks embracing change and staying bullish amid rebrand
Sep 17, 2026 8:45am
UK cost watchdog endorses Lilly's weekly insulin injectable
Aug 20, 2026 9:12am
Insulet, Calm to fill mental health gaps in diabetes treatment
Jul 14, 2026 3:00am
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
Jun 11, 2026 7:00am
Lilly yells ‘action’ on authentic patient portrayals at Tribeca
Jun 10, 2026 5:30pm
